Business
CSL (ASX:CSL) share price dips on latest AstraZeneca news
The CSL Limited (ASX: CSL) share price is down today as the Australian Government recommended that people under 50 should not take the AstraZeneca PLC (LSE: AZN) COVID-19 vaccine.
At the time of writing, shares in the pharmaceutical giant are trading for $264.20, down 0.65%. By comparison, the S&P/ASX 200 Index (ASX: XJO) is 0.43% lower.
With the latest vaccine developments potentially impacting the country’s return to post-COVID ‘normal’, the news may be behind today’s downward trend across the stock market.
Let’s take a closer look at last night’s developments and how the CSL share price is responding.
New vaccine recommendation
In another blow to the Federal Government’s delayed vaccine rollout (and the CSL share…
-
Business21 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Noosa News18 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference
-
Business18 hours agoDicker Data rides the AI trend to double digit growth
-
Business21 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy